Acurx Pharmaceuticals Inc. to Report Q1 2025 Earnings

Acurx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company based in White Plains, United States, is scheduled to release its first quarter 2025 financial results on May 13, 2025. The company, which specializes in developing a new class of antibiotics targeting bacterial infections, is listed on the Nasdaq and trades under the currency of USD.

Over the past year, Acurx Pharmaceuticals’ stock has experienced significant volatility. The company’s stock reached a 52-week high of $3.325 USD on July 17, 2024. However, it subsequently fell to a 52-week low of $0.3 USD on April 8, 2025. As of May 8, 2025, the stock price was recorded at $0.378 USD, reflecting a substantial decline from its peak.

The market capitalization of Acurx Pharmaceuticals stands at approximately $9,259,130 USD. The company’s operations are global, serving customers worldwide, and more information about their work and offerings can be found on their website at www.acurxpharma.com .

Investors and analysts are keenly awaiting the Q1 2025 earnings report to gain insights into the factors influencing the company’s stock performance. The report is expected to provide a clearer picture of the company’s financial health and strategic direction moving forward.